Analytical and Pharmacokinetics Core

$80,758U54FY2010CANIH

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Paper 38096474 Paper 36936967 Paper 36146933 Paper 34998171 Paper 34843648 Paper 34775659 Paper 34617445 Paper 33963786 Paper 33251789 Paper 32463690 Paper 32270047 Paper 32114218 Paper 31989142 Paper 31544862 Paper 30972374 Paper 30693332 Paper 30660473 Paper 30327876 Paper 30255248 Paper 30140713 Paper 30107215 Paper 29860139 Paper 29626548 Paper 29455066 Paper 29361211 Paper 29258739 Paper 29146244 Paper 28966368 Paper 28809532 Paper 28804994 Paper 28789965 Paper 28748125 Paper 28700955 Paper 28650437 Paper 28624669 Paper 28624477 Paper 28414916 Paper 28401174 Paper 28385609 Paper 28302144 Paper 28287740 Paper 28274796 Paper 28035321 Paper 27966988 Paper 27864344 Paper 27863995 Paper 27840166 Paper 27834949 Paper 27831902 Paper 27784746 Paper 27725955 Paper 27720926 Paper 27666558 Paper 27551741 Paper 27456556 Paper 27423326 Paper 27264609 Paper 27213045 Paper 27079967 Paper 26941036 Paper 26772430 Paper 26763733 Paper 26678179 Paper 26592524 Paper 26577747 Paper 26575637 Paper 26489694 Paper 26407672 Paper 26392803 Paper 26389971 Paper 26373346 Paper 26341695 Paper 26334519 Paper 26305294 Paper 26285063 Paper 26277065 Paper 26267360 Paper 26264646 Paper 26220272 Paper 26173794 Paper 26146545 Paper 26134311 Paper 26125606 Paper 26093057 Paper 26088284 Paper 25900441 Paper 25895870 Paper 25832087 Paper 25786195 Paper 25771011 Paper 25744827 Paper 25733311 Paper 25707978 Paper 25689735 Paper 25596376 Paper 25584654 Paper 25574586 Paper 25553823 Paper 25531409 Paper 25443790

Abstract

Core 1: Analytical and Pharmacokinetics Core PI: William Zamboni, Pharm. D., Ph.D. William Zamboni is an Associate Professor in the Eshelman School of Pharmacy. He is the Director of GLP Analytical Facility, Center for Experimental Therapeufics and the Director of the Translational Oncology and Nanoparticle Drug Development Inifiafive (T0ND2I) Lab at UNC. He has been involved in translational studies of anticancer agents for several years. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimizafion of the chemotherapeufic treatment of cancer. He is also developing nanosomal and nanoparticle anticancer agents and evaluating the relafionship between the disposition of these agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and are evaluafing potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents, and generate administration schedules to enhance selective tumor uptake.

View original record on NIH RePORTER →